Watanabe S, Takizawa K, Shimada S, Yamada K, Nakagawa H, Kukita A, Miura Y, Tsukinaga I, Tagami H, Tanita Y
Jpn J Antibiot. 1985 Mar;38(3):575-94.
Clinical effectiveness of TMS-19-Q, a new macrolide antibiotic, was evaluated in superficial infectious diseases classified into 6 groups at 13 departments of dermatology. The results obtained were as follows: Final global improvement rating in 311 cases were excellent in 91, good in 158, fair in 45 and poor in 17 and the effective rate was 80.1%. Effective rates in each group were 71.1% in 1st group (folliculitis and acne pustulosa), 78.6% in 2nd group (furuncle, furunculosis and carbuncle), 100% in 3rd group (impetigo), 76.9% in 4th group (phlegmone, superficial lymphangitis, erysipelas and infectious paronychia), 88.7% in 5th group (inflammatory atheroma, subcutaneous abscess, hidradenitis suppurative and acne conglobata) and 77.3% in 6th group (secondary infection). Dominant strains isolated were S. aureus (40.7%), S. epidermidis (26.9%) and anaerobic bacteria (20.8%). S. aureus was frequently isolated from most of all disease. On the other hand, S. epidermidis and anaerobic bacteria were isolated mainly from 1st and 5th group. Optimum daily doses would be over 600 mg. Slight adverse reactions such as gastrointestinal disorders, eruption and malaise were observed in 12 cases.
在13个皮肤科对一种新型大环内酯类抗生素TMS - 19 - Q在分为6组的浅表感染性疾病中的临床疗效进行了评估。获得的结果如下：311例患者的最终整体改善评级为：优91例，良158例，中45例，差17例，有效率为80.1%。各组的有效率分别为：第1组（毛囊炎和脓疱性痤疮）71.1%，第2组（疖、疖病和痈）78.6%，第3组（脓疱病）100%，第4组（蜂窝织炎、浅表淋巴管炎、丹毒和感染性甲沟炎）76.9%，第5组（炎性粉瘤、皮下脓肿、化脓性汗腺炎和聚合性痤疮）88.7%，第6组（继发感染）77.3%。分离出的优势菌株为金黄色葡萄球菌（40.7%）、表皮葡萄球菌（26.9%）和厌氧菌（20.8%）。金黄色葡萄球菌在大多数疾病中都经常被分离出来。另一方面，表皮葡萄球菌和厌氧菌主要从第1组和第5组中分离出来。最佳日剂量应为600毫克以上。12例患者出现了轻微的不良反应，如胃肠道不适、皮疹和不适。
